<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(22)</volume><submitter>Zhu Z</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Gastric cancer (GC) is a heterogeneous disease, and is a leading cause of cancer deaths in Eastern Asia. Genomic analysis, such as whole-exome sequencing (WES), can help identify key genetic alterations leading to the malignancy and diversity of GC, and may help identify new drug targets.&lt;h4>Methods&lt;/h4>We identified genomic alterations in a cohort of 38 GC patients, including 26 metastatic and 12 non-metastatic patients. We analyzed the association between novel gene mutations and copy number variations (CNVs) with tumor metastasis and patient survival.&lt;h4>Results&lt;/h4>A number of significantly mutated genes in somatic and germline cells were identified. Among them, &lt;i>ATAD3B&lt;/i> somatic mutation, a potential biomarker of immunotherapy in stomach cancers, was associated </pubmed_abstract><journal>Annals of translational medicine</journal><pagination>1484</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7729362</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Whole-exome sequencing identifies prognostic mutational signatures in gastric cancer.</pubmed_title><pmcid>PMC7729362</pmcid><pubmed_authors>Shi M</pubmed_authors><pubmed_authors>Cha W</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Dai C</pubmed_authors><pubmed_authors>Fu H</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>You Q</pubmed_authors><pubmed_authors>Wang G</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Yu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Whole-exome sequencing identifies prognostic mutational signatures in gastric cancer.</name><description>&lt;h4>Background&lt;/h4>Gastric cancer (GC) is a heterogeneous disease, and is a leading cause of cancer deaths in Eastern Asia. Genomic analysis, such as whole-exome sequencing (WES), can help identify key genetic alterations leading to the malignancy and diversity of GC, and may help identify new drug targets.&lt;h4>Methods&lt;/h4>We identified genomic alterations in a cohort of 38 GC patients, including 26 metastatic and 12 non-metastatic patients. We analyzed the association between novel gene mutations and copy number variations (CNVs) with tumor metastasis and patient survival.&lt;h4>Results&lt;/h4>A number of significantly mutated genes in somatic and germline cells were identified. Among them, &lt;i>ATAD3B&lt;/i> somatic mutation, a potential biomarker of immunotherapy in stomach cancers, was associated </description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-04-04T23:46:44.876Z</modification><creation>2025-04-04T23:46:44.876Z</creation></dates><accession>S-EPMC7729362</accession><cross_references><pubmed>33313229</pubmed><doi>10.21037/atm-20-6620</doi></cross_references></HashMap>